Showing results (21-30 of 25) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Journal of Cancer Research and Clinical Oncology|February 21, 2019
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progressionMartin Schuler, Eng-Huat Tan, Kenneth O'Byrne, et al.The Lancet. Oncology|April 17, 2016
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialKeunchil Park, Eng-Huat Tan, Ken O'Byrne, et al.The Lancet. Oncology|January 16, 2015
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih-Hsin Yang, Yi-Long Wu, Martin Schuler, et al.The New England Journal of Medicine|October 25, 2024
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.The New England Journal of Medicine|November 4, 2022
Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.Pageof 3